A new generation of Alzheimer’s treatments — groundbreaking, disease-modifying monoclonal antibody drugs — is on the rise, and two so far have hit the…
In January of 2023, the Food and Drug Administration approved the second anti-amyloid therapy for Alzheimer’s disease, Leqembi (generic name lecanemab). A new Alzheimer’s…
I’m writing from Amsterdam, where this past week, the Being Patient editorial team has been reporting on the biggest news from the Alzheimer’s Association…
Drugmaker Alzheon is currently running clinical trials on a new disease-modifying Alzheimer’s treatment: valiltramiprosate, or ALZ-801. While, like the new buzzy new Alzheimer’s monoclonal…
We arrived at the emergency vet at 1 a.m. Our 10-month-old kitten, Pippin, had started breathing oddly earlier in the day but we thought…
American pharmaceutical company Eli Lilly announced in May 2023 that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to…
On July 6, 2023, the U.S. Food and Drug Administration fully approved the Alzheimer’s drug Leqembi (generic name lecanemab), a monoclonal antibody drug for…
Last week I had the opportunity to be the guest speaker of Grand Rounds at the Memory and Aging Center at the University of…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
Despite decades of study, the underlying cause of Alzheimer’s continues to evade scientists. Because it’s such a mystery, there are only six drugs approved for…
In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
Last April, the Centers for Medicare and Medicaid Services (CMS) decided to limit the coverage of the controversial Alzheimer’s drug Aduhelm and similar drugs…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…